In 2015, UCB announced the sale of its branded generics business in India and South Asia to Dr. Reddy's Laboratories for INR 8 billion ($128.38 million).
Di 2015, UCB mengumumkan penjualan divisi obat generik bermerek di India dan Asia Selatan ke Dr. Reddy's Laboratories senilai 8 miliar rupee ($128.38 juta).